Treatment outcomes of daptomycin- and vancomycin-resistant Enterococcus faecium bloodstream infection
JAC-Antimicrobial Resistance · 30.04.2026 · 8 (3)
DOI: 10.1093/jacamr/dlag108 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 12.06.2026. Verfasst von Wei-Ting Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital, 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City 100225, Taiwan. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taiwan, Ministry of Health and Welfare, Taiwan, National Taiwan University Hospital.
Abstract (Originalsprache)
Objectives
Among patients with daptomycin-resistant and vancomycin-resistant Enterococcus faecium bloodstream infection (BSI), the optimal definitive therapy is uncertain. We estimated the dose effect of daptomycin (≥11 mg/kg versus 8 to <11 mg/kg) on 28-day mortality and exploratorily described outcomes in patients treated with linezolid.
Methods
Adults with VRE BSI who received linezolid or daptomycin ≥8 mg/kg were included. Post hoc daptomycin MICs were determined by Sensititre broth microdilution (BMD), and episodes with MIC ≥8 mg/L were analyzed. The primary outcome was 28-day in-hospital mortality.
Results
Among 130 patients with daptomycin-resistant VRE BSI, 110 received daptomycin and 20 received linezolid. Within the daptomycin group, 28-day mortality was 55.1% (43/78) with daptomycin 8 to <11 mg/kg and 34.4% (11/32) with daptomycin ≥11 mg/kg. In adjusted analysis, daptomycin 8 to <11 mg/kg was associated with higher mortality than daptomycin ≥11 mg/kg [adjusted odds ratio (aOR) 3.11, 95% CI 1.13 to 8.56, P = 0.03]. Among isolates with daptomycin MIC = 8 mg/L, 28-day mortality was 54.9% in patients treated with daptomycin 8 to <11 mg/kg versus 29.6% treated with daptomycin ≥11 mg/kg (P = 0.04); no benefit was seen for MIC ≥16 mg/L (P > 0.99). 28-day mortality was 49.1% (54/110) with daptomycin and 35.0% (7/20) with linezolid (P = 0.33); linezolid was not associated with lower mortality than daptomycin in adjusted analysis (P = 0.48).
Conclusions
In daptomycin-resistant VRE BSI, daptomycin ≥11 mg/kg was associated with lower 28-day mortality than daptomycin 8 to <11 mg/kg, particularly at MIC = 8 mg/L. Comparisons with the small linezolid arm are exploratory and underpowered. Larger studies are needed to confirm these hypothesis-generating findings.
Autor:innen und Institutionen
- Department of Internal Medicine, National Taiwan University Hospital, 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City 100225, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County 640203, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu City 300195, Taiwan.
ORCID-Profile: Yee-Chun Chen, Shan-Chwen Chang
Förderung
- National Science and Technology Council, Taiwan
- Ministry of Health and Welfare, Taiwan
- National Taiwan University Hospital
Zitieren
APA
Lin, W. T., Yang, J. L., Lin, C. Y., Huang, S. H., Chuang, Y. C., Wang, J. T., Chen, Y. C., & Chang, S. C. (2026). Treatment outcomes of daptomycin- and vancomycin-resistant Enterococcus faecium bloodstream infection. JAC-Antimicrobial Resistance, 8(3). https://doi.org/10.1093/jacamr/dlag108
Vancouver
Lin WT, Yang JL, Lin CY, Huang SH, Chuang YC, Wang JT, et al. Treatment outcomes of daptomycin- and vancomycin-resistant Enterococcus faecium bloodstream infection. JAC-Antimicrobial Resistance. 2026;8(3). doi:10.1093/jacamr/dlag108
BibTeX
@article{Lin2026,
author = {Lin, Wei-Ting and Yang, Jia-Ling and Lin, Chi-Ying and Huang, Sung-Hsi and Chuang, Yu-Chung and Wang, Jann-Tay and Chen, Yee-Chun and Chang, Shan-Chwen},
title = {Treatment outcomes of daptomycin- and vancomycin-resistant Enterococcus faecium bloodstream infection},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {3},
doi = {10.1093/jacamr/dlag108}
}
EUVIMED